Highlights
1 patentProfile claimed by owner
About
Small Molecule Inhibitors of TRPV3
Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need. TRPV3 has been extensively evaluated as a target for drug development, identified as the cause of Olmsted syndrome in humans, and shows involvement in various skin disorders including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.
Identity
| Name | Kamari Pharma |
|---|---|
| Slug | kamari-pharma |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Onxyf8LDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Pinhas Sapir Street 3, Ness Ziona, Israel |
Web & social
| Website | https://www.orvidapharma.com |
|---|---|
| https://www.linkedin.com/company/83017944 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biopharmaceuticaldrug-developmentdermatologypharma-companiesskinrare-diseasespharmaceuticals
Funding
| Total raised | $31.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}